Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event
December 29, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout
December 01, 2021 08:00 ET
|
Selecta Biosciences, Inc.
-DISSOLVE program on track with 12-month study fully enrolled--DISSOLVE II on track for full enrollment in early 2022--Top-line data from Phase 3 DISSOLVE program expected in H2 2022- WATERTOWN,...
Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia
November 24, 2021 16:15 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference
November 11, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
November 09, 2021 08:00 ET
|
Selecta Biosciences, Inc.
-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform- -Reported topline data from SEL-399 (empty AAV8 capsid in...
Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy
November 08, 2021 08:12 ET
|
Selecta Biosciences, Inc.
- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 - - With co-administration of AAV8 empty capsids and ImmTOR, Selecta...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
November 05, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
October 26, 2021 08:00 ET
|
Selecta Biosciences, Inc.
Leveraging Ginkgo’s cell programming platform and Selecta’s ImmTOR platform to create potentially transformative enzymatic therapies Selecta gains rights to develop and commercialize select...
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
October 21, 2021 08:00 ET
|
Selecta Biosciences, Inc.
- Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease - - Selecta combines ImmTOR™ platform with Genovis’ novel IgG protease, Xork, to unlock the full...
Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit
October 20, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...